An observational study in Germ Cell Tumor and Testicular Tumor, sponsored by Memorial Sloan Kettering Cancer Center. Recruiting at 8 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-04.
Sponsored by Memorial Sloan Kettering Cancer Center · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 94 studies in Neoplasms, Germ Cell and Embryonal with a site in United States — 25 open to participants now, 36 under way, 3 of them phase 3. Neoplasms, Germ Cell and Embryonal · United States.
Among the 94 studies in Neoplasms, Germ Cell and Embryonal with a site in United States, this one is the 4th largest by planned enrollment of the 13 observational ones that give a count, is one of 6 that started in 2014, is one of 13 observational ones, reaches primary completion later than 20 of the 35 other live ones, and was the 32nd registered.
167 studies on the registry are indexed under Neoplasms, Germ Cell and Embryonal; 49 are open to participants now.
Browse Neoplasms, Germ Cell and Embryonal studies →25 of the 94 studies in Neoplasms, Germ Cell and Embryonal with a site in United States are open now. Recruiting first, the newest first:
Loma Linda University · Sites in United States
Ages 18+ · Men only
Indiana University · Sites in United States
Ages 18+
University of California, Irvine · Sites in United States
Ages 18+
Children's National Research Institute · Sites in United States
Ages 3–21
Indiana University · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 40 Neoplasms, Germ Cell and Embryonal studies recruiting now, 20 (50%) set no upper age limit and 16 (40%) stop at 75 or younger; 22 take children under 18; 1 takes healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
94 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 42 · Phase 2 39 · Phase 3 4
First in 1998; this study’s year is marked. 6 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,000 is above the median of 290 across 34 observational studies indexed under Neoplasms, Germ Cell and Embryonal.
Median enrollment 36 across the 81 interventional studies, 213 across the 13 observational. Of the 51 that completed or were terminated, 21 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 94 have an industry lead sponsor. The 10 most frequent:
Memorial Sloan Kettering Cancer Center is the lead sponsor of 1,964 studies on the registry; 325 are open to participants now.
Of its 135 completed or terminated interventional studies of FDA-regulated products, 71 (53%) have results posted.
Memorial Sloan Kettering Cancer Center has 5 studies filed under Neoplasms, Germ Cell and Embryonal — fewer than ten, so there is no comparison to draw.
15 of the studies in Neoplasms, Germ Cell and Embryonal with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03067181Phase 3Children's Oncology GroupActive Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors | 2027-06-30 |
| NCT03158064Memorial Sloan Kettering Cancer CenterEvaluating Immune Therapy, Duravalumab (MEDI4736) With Tremelimumab for Relapsed/Refractory Germ Cell Tumors | 2026-11 |
| NCT01890486Wake Forest University Health SciencesThe Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen | 2026-12 |
| NCT04308330New York Medical CollegeVorinostat in Combination With Chemotherapy in Relapsed/Refractory Solid Tumors and CNS Malignancies | 2026-12-31 |
| NCT04435756SWOG Cancer Research NetworkA Study of miRNA 371 in Patients With Germ Cell Tumors | 2027-01-01 |
Add all 15 to your calendar (.ics) → With an account.
Among the 94 studies in Neoplasms, Germ Cell and Embryonal with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is being done to create a registry to help us learn more about germ cell tumors (GCT) and other testicular tumors. The registry will include people with these tumors and also relatives and unrelated people without these tumors. This study will help us learn more about the prevention, diagnosis, treatment and outcome of these tumors. Studying relatives of patients and people unrelated to patients with GCT and other testicular tumors will help us understand why some people get these tumors and why some people don't.
At MSKCC, the following outpatient clinics will be used to recruit GCT and testicular tumor cases and controls: Urology (Department of Surgery), Gynecologic Oncology (Department of Surgery) Clinical Genetics, Genitourinary Oncology (Department of Medicine), and Gynecologic Medical Oncology (Department of Medicine).
Case Cohort
Family Member Cohort
Control Cohort
Exclusion Criteria:
patients with testicular GCTs and non-GCT testicular tumors, extragonadal male GCTs, and female GCTs,
Behavioral: Questionnaires · Other: sample of blood or saliva
relatives of patients with GCTs or testicular tumors
Behavioral: Questionnaires · Other: sample of blood or saliva
healthy controls who are unrelated to Groups A or B and do not have a personal history of cancer nor a family history of GCT or non-GCT testicular tumors
Behavioral: Questionnaires · Other: sample of blood or saliva
A sample of blood or saliva will be obtained for DNA extraction. Approximately 2-4 tubes of blood will be collected or one tablespoon of saliva. If a participant has already provided a DNA sample for another MSKCC IRB approved protocol, they may not need to provide an additional sample.
creation of a Germ Cell Tumor and testicular tumor registry
We will collect clinical data including diagnosis date, pathology, family history, and risk factors in patients with GCT-TT.
Time frame: 5 years
Started Jan 2014 (actual). Primary completion is estimated for Jan 2028, 168 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Neoplasms, Germ Cell and Embryonal →
Memorial Sloan Kettering Cancer Center →